Maraviroc and Fluconazole (Triflucan 100 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Moderate CYP3A inhibition may increase maraviroc exposure.
Clinical significance and safety
EMA maraviroc information advises caution with fluconazole, the active ingredient in Triflucan 100 mg. Population pharmacokinetic data did not indicate that routine maraviroc adjustment was required; this differs from the strong-inhibitor rule. The clinician should review tolerability, renal function and all other medicines rather than applying that rule automatically.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.